Nursing Review Issue 1 | Jan-Feb 2019 | Page 21

specialty focus a list of oncogenes and asked questions about the ages of the genes and their function after they cluster around certain properties. What she found was that a set of these oncogenes are just like – the technical term is homologues – the genes you find in bacteria that can turn up the mutation rates of bacteria when they’re under stress. There’s a well-known phenomenon that if you starve bacteria – so if they normally feed on glucose and you deprive them of glucose – they can metabolise other sugars, and they will turn up their rates of mutation to find one that will enable them to metabolise other sources of food. It’s often called an SOS response, and it’s been much studied. So the mutation rate is actually not just God given, it’s partially under the control of organisms. They can tune their own mutation rates and, lo and behold, a subset of cancer genes has that property of being just like the genes in bacteria of turning up the mutation rate. Now, one of the hallmarks of cancer is its rapid rate of mutation. That’s what makes it so hard to treat with chemotherapy because it just evolves resistance to any particular drug. So the discovery that this is a sort of self- inflicted process, that the mode of mutation is the same when you look at the pattern of mutation in cancer cells and the pattern of mutation in bacterial cells in quite some detail, they really do match up. This is a very ancient stress response. So the therapeutic aspects of this are pretty obvious. The more stressed a cell feels, the more likely it is to invoke this SOS response. And so the standard of practice in cancer treatment – in many cases, not all – tends to be maximum tolerable dose: you flood the patient with a toxin in the hope that the cancer dies before the patient dies. We think we should get away from that, but that’s likely to be counterproductive because the elevation of stress on the cancer cell is much more likely to trigger this SOS response. What we would like to see is cancer that, instead of trying to annihilate it, we try to live with it. That is, use therapeutic agents, but use them in the lowest doses that can hold the cancer in check. This is rather a psychological issue. Many people react badly to cancer. They feel, “I’ve got cancer. I want every cancer cell in my body eradicated.” Well, that is simply impossible. We need to get used to the idea that cancer is a normal part of ageing, that you have cancers in you and most of them are managed okay, and if one of them breaks out and the body’s not coping with it, we help the body to maintain it and treat it as a chronic disease, not something that we must eradicate with toxins and so on. One of the ideas suggested in your piece was potentially treating cancer with the introduction of viruses. Yes. About 100 years ago, an American physician, William Coley, noticed that some cancers would spontaneously vanish if the patient got an infectious disease. This was more common before the era of sterilisation. So Coley started deliberately infecting his cancer patients with a particular disease. The great hope in cancer treatment at the moment seems to be immunotherapy, where you’d try to boost the body’s own immune system to take care of the cancer. The standard explanation for Coley’s results is that the infection boosted the immune system and the cancer was knocked off as collateral damage. We think that at least part of the story is that the cancer tumours themselves are more susceptible to infection than the healthy tissues. And part of the reason for that is one of the hallmarks of cancer is it decouples from the body’s immune system. It can screen the immune system out. That’s one of the ways it gets around the immune system trying to attack it. So we think that tumours are actually more vulnerable to infections than the healthy part of the body. This is another way to interpret Coley’s experiments. We should think seriously about injecting tumour tissue and with a variety of – it doesn’t have to be bacteria, it can be viruses, or even a fungal agent. The point being that tumours are more vulnerable to disease, so that gives another therapeutic line of attack that I think is worth investigating. And a few people do seem to be producing results around those ideas. But this is very much in its early stages. What are the possible implications from your theories for the health system and our approach to cancer? It’s unrealistic to expect there to be a cure. I call this the ‘lure of the cure’ – the idea that there’s a pill that will make it go away. Some sort of general-purpose cancer pill I think is a complete waste of time and money. We’re not going to ever achieve that. There have been some success stories with individual cancers, and it would be wrong to belittle that. Childhood leukaemia, for example, is largely conquered, if we’re going to use that sort of military expression. But I think in the vast majority of cancers, we have to get to this point of view that they should be managed rather than eradicated. I’m a fan of looking for ways of stabilising cancer other than using chemical toxins. One idea I’ve been interested in – though there haven’t been any real clinical trials – is hyperbaric oxygen therapy. The point here is that a cancer, in its reversion to this more primitive phenotype, switches to a different form of metabolism. Healthy cells use a process called oxidative phosphorylation to get their energy. Cancer cells use a different mechanism, called glycolysis. It takes sugar and it’s not very energy efficient, but it’s good at making biomass. So, if the name of the game is more bulk, which is what humans do, but they need less energy, then this glycolysis is a good way to go. It’s often called fermentation as well because it’s the same process. In a nutshell, healthy cells like lots of oxygen; cancer cells can work in very low levels of oxygen, a bit like it was on Earth two billion years ago. So, they like lots of sugar and not much oxygen. So the plan is you hold them in check. You turn this around the other way: you turn off the sugar, through diet, and turn up the oxygen through hyperbaric oxygen therapy, which is available for use for many conditions. This is something which is already familiar in various medical treatments: you put the patient into a chamber at two atmospheres, pure oxygen, for half an hour or something. So we think combined with something like a ketogenic diet, hyperbaric oxygen therapy could stabilise tumours, and that’s all you need to do. I should emphasise, again, that you don’t have to eradicate them, so long as tumours don’t spread, or if they do spread, they don’t cause problems in the secondary side. So long as it’s stable, what more could you want? It’s very hard, though, with the way the medical system works, to get much traction behind something that doesn’t involve a new chemical agent or something that a drug company can make. Oxygen is pretty much free; you can change your diet for nothing, and what I’m advocating here is not anything that’s likely to make money. So, under those circumstances, it’s hard to get anyone to pay for a clinical trial, because the only reason people do clinical trials is if there’s likely to be a large profit at the end of it – a sad state of affairs.  ■ nursingreview.com.au | 19